Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Peterson Wealth Services

Peterson Wealth Services increased its position in Novo Nordisk A/S (NYSE:NVO) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,604 shares of the company’s stock after acquiring an additional 435 shares during the period. Novo Nordisk A/S makes up 1.8% of Peterson Wealth Services’ portfolio, making the stock its 16th biggest position. Peterson Wealth Services’ holdings in Novo Nordisk A/S were worth $4,201,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Cornerstone Planning Group LLC bought a new position in Novo Nordisk A/S in the 2nd quarter valued at about $29,000. Tower Research Capital LLC TRC grew its position in Novo Nordisk A/S by 165.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after buying an additional 124 shares in the last quarter. Pacific Center for Financial Services grew its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Valued Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $28,000. Finally, Copeland Capital Management LLC grew its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded down $0.49 during trading hours on Thursday, hitting $124.04. 667,553 shares of the company’s stock traded hands, compared to its average volume of 4,850,171. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The company’s fifty day simple moving average is $126.28 and its two-hundred day simple moving average is $110.42. The company has a market cap of $556.63 billion, a price-to-earnings ratio of 45.69, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.33 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a $0.664 dividend. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.